Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol

Brendan Seng Hup Chia, Jing Yun Leong, Ashley Li Kuan Ong, Cindy Lim, Shi Hui Poon, Melvin Lee Kiang Chua, Kevin Lee Min Chua, Grace Kusumawidjaja, Eu Tiong Chua, Fuh Yong Wong, Tih Shih Lee, Brendan Seng Hup Chia, Jing Yun Leong, Ashley Li Kuan Ong, Cindy Lim, Shi Hui Poon, Melvin Lee Kiang Chua, Kevin Lee Min Chua, Grace Kusumawidjaja, Eu Tiong Chua, Fuh Yong Wong, Tih Shih Lee

Abstract

Background: Recent evidence supports hippocampal avoidance with whole brain radiotherapy (HA-WBRT) as the recommended treatment option in patients with good prognosis and multiple brain metastases as this results in better neurocognitive preservation compared to whole brain radiotherapy. However, there is often poor tumour control with this technique due to the low doses given. Stereotactic Radiosurgery (SRS), a form of focused radiotherapy which is given to patients who have a limited number of brain metastases, delivers a higher radiation dose to the metastases resulting in better target lesion control. With improvements in radiation technology, advanced dose-painting techniques now allow a simultaneous integrated boost (SIB) dose to lesions whilst minimising doses to the hippocampus to potentially improve brain tumour control and preserve cognitive outcomes. This technique is abbreviated to HA-SIB-WBRT or HA-WBRT+SIB.

Methods: We hypothesise that the SIB in HA-SIB-WBRT (experimental arm) will result in better tumour control compared to HA-WBRT (control arm). This may also lead to better intracranial disease control as well as functional and survival outcomes. We aim to conduct a prospective randomised phase II trial in patients who have good performance status, multiple brain metastases (4-25 lesions) and a reasonable life expectancy (> 6 months). These patients will be stratified according to the number of brain metastases and randomised between the 2 arms. We aim for a recruitment of 100 patients from a single centre over a period of 2 years. Our primary endpoint is target lesion control. These patients will be followed up over the following year and data on imaging, toxicity, quality of life, activities of daily living and cognitive measurements will be collected at set time points. The results will then be compared across the 2 arms and analysed.

Discussion: Patients with brain metastases are living longer. Maintaining functional independence and intracranial disease control is thus increasingly important. Improving radiotherapy treatment techniques could provide better control and survival outcomes whilst maintaining quality of life, cognition and functional capacity. This trial will assess the benefits and possible toxicities of giving a SIB to HA-WBRT.

Trial registration: Clinicaltrials.gov identifier: NCT04452084 . Date of registration 30th June 2020.

Keywords: Brain metastases; Hippocampal-avoidance whole brain radiotherapy; Study protocol; Whole brain radiotherapy.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Project Schema

References

    1. Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Gonçalves A, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol. 2012;7:77. doi: 10.1186/1748-717X-7-77.
    1. Eichenbaum H. The hippocampus and declarative memory: cognitive mechanisms and neural codes. Behav Brain Res. 2001;127:199–207. doi: 10.1016/S0166-4328(01)00365-5.
    1. Wheeler SM, McLelland VC, Sheard E, McAndrews MP, Rovet JF. Hippocampal functioning and verbal associative memory in adolescents with congenital hypothyroidism. Front Endocrinol (Lausanne) 2015;6:163. doi: 10.3389/fendo.2015.00163.
    1. Papanicolaou AC, Simos PG, Castillo EM, Breier JI, Katz JS, Wright AA. The hippocampus and memory of verbal and pictorial material. Learn Mem. 2002;9:99–104. doi: 10.1101/lm.44302.
    1. Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal Dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol. 2012;83:e487–e493. doi: 10.1016/j.ijrobp.2011.10.021.
    1. Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol. 2020;38:1019–1029. doi: 10.1200/JCO.19.02767.
    1. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672. doi: 10.1016/S0140-6736(04)16250-8.
    1. Sperduto PW, Shanley R, Luo X, Andrews D, Werner-Wasik M, Valicenti R, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA) Int J Radiat Oncol Biol Phys. 2014;90:526–531. doi: 10.1016/j.ijrobp.2014.07.002.
    1. Patil CG, Pricola K, Sarmiento JM, Garg SK, Bryant A, Black KL. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev. 2017. 10.1002/14651858.CD006121.pub4.
    1. Awad R, Fogarty G, Hong A, Kelly P, Ng D, Santos D, et al. Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases – the first Australian experience. Radiat Oncol. 2013;8:62. doi: 10.1186/1748-717X-8-62.
    1. Oehlke O, Wucherpfennig D, Fels F, Frings L, Egger K, Weyerbrock A, et al. Ganzhirnbestrahlung mit Hippocampusschonung und Dosiseskalation bei multiplen Hirnmetastasen: Lokale Tumorkontrolle und Überleben. Strahlentherapie Onkol. 2015;191:461–469. doi: 10.1007/s00066-014-0808-9.
    1. Popp I, Rau S, Hintz M, Schneider J, Bilger A, Fennell JT, et al. Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Cancer. 2020;126:2694–2703. doi: 10.1002/cncr.32787.
    1. Kim KH, Cho BC, Lee CG, Kim HR, Suh YG, Kim JW, et al. Hippocampus-sparing whole-brain radiotherapy and simultaneous integrated boost for multiple brain metastases from lung adenocarcinoma. Technol Cancer Res Treat. 2016;15:122–129. doi: 10.1177/1533034614566993.
    1. Westover KD, Mendel JT, Dan T, Kumar K, Gao A, Pulipparacharuv S, et al. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro-Oncology. 2020. 10.1093/neuonc/noaa092.
    1. Zhong J, Waldman AD, Kandula S, Eaton BR, Prabhu RS, Huff SB, et al. Outcomes of whole-brain radiation with simultaneous in-field boost (SIB) for the treatment of brain metastases. J Neuro-Oncol. 2020;147:117–123. doi: 10.1007/s11060-020-03405-y.
    1. Grosu AL, Frings L, Bentsalo I, Oehlke O, Brenner F, Bilger A, et al. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG) BMC Cancer. 2020;20:532. doi: 10.1186/s12885-020-07011-z.
    1. Seng Hup Chia B, Li Kuan Ong A, Master Z. RTHP-26. Dosimetric feasibility study using hippocampal avoidance with simultaneous integrated boost whole brain radiotherapy. (HA-SIB-WBRT) Neuro Oncol. 2019;21(Supplement_6):vi215. doi: 10.1093/neuonc/noz175.897.
    1. Soliman H, Ruschin M, Angelov L, Brown PD, Chiang VLS, Kirkpatrick JP, et al. Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2018;100:436–442. doi: 10.1016/j.ijrobp.2017.09.047.
    1. Lin N, Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, et al. Response assessment criteria for brain metastases: proposal from the RANO group 2015. doi:10.1016/S1470-2045(15)70057-4.
    1. Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2018;1:CD003869. doi: 10.1002/14651858.CD003869.pub4.
    1. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15:387–395. doi: 10.1016/S1470-2045(14)70061-0.
    1. Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, et al. Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys. 2019;104:1091–1098. doi: 10.1016/j.ijrobp.2019.03.052.
    1. McTyre E, Ayala-Peacock D, Contessa J, Corso C, Chiang V, Chung C, et al. Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis. Ann Oncol. 2018;29:497–503. doi: 10.1093/annonc/mdx740.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel